GlassScriptPhysician profile
Fazia Mir
NPI 1679886394
$97,560.17
in general payments reported to CMS, 2019-2025
14 companies · $52K in 2025
The $52K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $77.16 · 2021: $71.97 · 2022: $6,982 · 2023: $18K · 2024: $20K · 2025: $52K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $82K · Food and Beverage: $3,454 · Travel and Lodging: $3,215 · Consulting Fee: $1,650 · Education: $55.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $81,835.50 |
| Food and Beverage | $3,453.90 |
| Travel and Lodging | $3,215.14 |
| Consulting Fee | $1,650.00 |
| Education | $55.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $61,492.54 | 2019-2025 | |
| Janssen Biotech, INC. | $32,910.86 | 2022-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $1,815.86 | 2023 | Zeposia |
| Medtronic, INC. | $569.99 | 2024-2025 | Gi Genius, Endoflip |
| Takeda Pharmaceuticals U.S.A., INC. | $267.51 | 2020-2025 | Eohilia, Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $152.71 | 2019-2024 | Xifaxan |
| Pfizer INC. | $82.59 | 2024-2025 | |
| Gilead Sciences, INC. | $78.13 | 2019-2020 | |
| Celgene Corporation | $69.91 | 2023-2024 | Zeposia |
| Boston Scientific Corporation | $37.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $24.90 | 2023 | Terlivaz |
| Allergan, INC. | $23.28 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $20.32 | 2025 | Iqirvo |
| Fresenius Kabi USA, LLC | $14.12 | 2024 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fazia Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.